Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Radionetics Oncology Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are handled by 2 distinct examiners, but they are both located within 1 distinct art unit. The busiest examiner is PERREIRA, MELISSA JEAN, who is responsible for 1 pending office action. Since there are 2 distinct examiners for 2 total actions, each examiner is handling exactly one case. The fact that both examiners are in the same distinct art unit suggests a very narrow technical focus for the company's current pending applications.
This profile shows a small but technically concentrated prosecution footprint. While practitioners must deal with 2 different individuals, they only need to navigate the standards and policies of a single art unit. The concentration of both pending actions within 1 distinct art unit suggests that the company's technology is highly specialized. While 2 distinct examiners are involved, the shared art unit environment may lead to similar prior art citations or procedural requirements across both cases. Practitioners should focus on the specific requirements of this single art unit while adapting to the individual styles of PERREIRA, MELISSA JEAN and the other assigned examiner to ensure favorable results for these 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERREIRA, MELISSA JEAN | 1 | 52.1% | +25.7% |
| ROGERS, JAMES WILLIAM | 1 | 46.1% | +22.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19394360 | NEUROTENSIN RECEPTOR 1 (NTSR1) TARGETED THERAPEUTICS AND USES THEREOF | PERREIRA, MELISSA JEAN | — |
| 18513230 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | ROGERS, JAMES WILLIAM | — |
| Art Unit | Apps |
|---|---|
| 1618 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19394360 | NEUROTENSIN RECEPTOR 1 (NTSR1) TARGETED THERAPEUTICS AND USES THEREOF | PERREIRA, MELISSA JEAN | 1618 | §112 | Non-Final OA | — | Pending | Nov 19, 2025 |
| 18513230 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | ROGERS, JAMES WILLIAM | 1618 | §103 | Final Rejection | — | Pending | Nov 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRadionetics Oncology Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Melissa Jean Perreira has the most, with 1 of Radionetics Oncology Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
